Gene & Cell Therapy Testing

11 07, 2023

Enhancing Safety and Efficacy – Biodistribution Services for Advanced Cell and Gene Therapies

2023-07-11T18:18:43+00:00

As the field of advanced cell and gene therapies continues to grow exponentially, ensuring their safety and efficacy becomes paramount. Biodistribution studies, which evaluate the distribution of viral vectors and transgenes in the body, play a crucial role in pre-clinical pharmacokinetics and toxicity assessments...

Enhancing Safety and Efficacy – Biodistribution Services for Advanced Cell and Gene Therapies2023-07-11T18:18:43+00:00
31 05, 2023

Cell Therapy Potency Assay Summit – 2023

2025-03-14T19:36:45+00:00

Ensure the Success of Your Cell Therapy Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Cell Therapy Potency Assay Summit – 20232025-03-14T19:36:45+00:00
16 05, 2023

New preclinical data from Sana Biotechnology highlights the potential of CAR T cell therapy

2024-07-10T19:48:37+00:00

Preclinical data demonstrates that hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in a non-human primate model and long-term survival and immune evasion was at least equivalent to the survival of autologous iPSCs...

New preclinical data from Sana Biotechnology highlights the potential of CAR T cell therapy2024-07-10T19:48:37+00:00
2 05, 2023

Quality control for gene therapies

2025-06-13T22:01:25+00:00

Strict quality requirements for gene therapies are designed to ensure the safety, efficacy, and consistency of these innovative treatments, and to minimize the risks associated with their use. These requirements are necessary to provide confidence to regulatory agencies, healthcare providers, and patients that gene therapies are safe and effective.

Quality control for gene therapies2025-06-13T22:01:25+00:00
11 04, 2023

Protein expression biodistribution studies

2023-04-11T16:17:21+00:00

Protein expression analysis is a critical process for researchers in the life sciences industry. The ability to accurately and reliably measure protein expression and distribution is essential for understanding the underlying biological mechanisms of disease and for developing effective therapeutic interventions...

Protein expression biodistribution studies2023-04-11T16:17:21+00:00
4 04, 2023

Gene therapy developers can benefit from orphan drug and rare pediatric disease designations

2024-07-13T13:30:32+00:00

Providing an overview of the submissions process and examples of U.S. Food and Drug Administration (FDA) applications for Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD), a new article can help developers of gene therapies for rare genetic diseases...

Gene therapy developers can benefit from orphan drug and rare pediatric disease designations2024-07-13T13:30:32+00:00
28 03, 2023

NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder

2023-03-28T15:43:47+00:00

A single dose gene therapy designed to correct the underlying genetic defect, eladocagene exuparvovec (also called Upstaza and made by PTC Therapeutics), is infused directly into the brain through a minimally invasive procedure – the first gene therapy to be administered in this way...

NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder2023-03-28T15:43:47+00:00
21 03, 2023

Biodistribution testing of cell and gene therapies

2023-03-21T14:09:40+00:00

Cell and gene therapy drug products represent a rapidly growing field in the development of new treatments for a wide range of diseases. These therapies have the potential to revolutionize medicine by offering cures rather than just managing symptoms. However, with this potential comes unique challenges, particularly with regard to biodistribution testing...

Biodistribution testing of cell and gene therapies2023-03-21T14:09:40+00:00
20 03, 2023

Gene Therapy for Rare Disorders – 2023

2025-03-14T19:41:12+00:00

Non-clinical and clinical studies that evaluate pharmacokinetic (ADME) and toxicology characteristics are essential to determine cellular and gene therapy (CGT) product safety and efficacy. Studies on gene vector and transgene biodistribution (BD), gene expression, protein expression, viral shedding, vector integration...

Gene Therapy for Rare Disorders – 20232025-03-14T19:41:12+00:00
Go to Top